Pgiam BTIG has initiated Nektar Therapeutics ( NASDAQ: NKTR ) with a buy rating, citing the potential of rezpegaldesleukin, a potential first-in-class regulatory T cell stimulator, for autoimmune disorders and chronic inflammatory diseases. The firm has a Street-high price target of $4 (~242% upside based on Sept. 27 close).
.
